Sunitinib in Metastatic Renal Cell Carcinoma: The Pharmacological Basis of the Alternative 2/1 Schedule

Front Pharmacol. 2017 Aug 7:8:523. doi: 10.3389/fphar.2017.00523. eCollection 2017.

¹ Department of Clinical and Experimental Medicine, University of PisaPisa, Italy.
² Medical Oncology, Ospedale San Donato USL8, Istituto Toscano TumoriArezzo, Italy.

No abstract available

Keywords: efficacy; metastatic renal cell carcinoma; pharmacodynamics; pharmacokinetics; sunitinib; tolerability.